-
In a pilot study of ovarian cancer patients treated with sorafenib and bevacizumab, CA125 concentrations were shown to not correspond with imaging analyses in the assessment of treatment response. Thus, caution is raised about using this tumor marker alone in the assessment of treatment outcomes for patients treated with newer, molecularly-targeted therapies.
-
-
-
In a randomized, prospective trial, anemic chemotherapy-receiving patients received either darbepoetin alone or darbepoetin with intravenous ferric gluconate. The group that received the added ferric gluconate had a significantly higher rate of achieving objective criteria for anemia improvement. The iron infusions were associated with no observed toxicity.
-
Hypereosinophilic syndrome (HES) is a spectrum of diseases where a primary cause of eosinophilia can not be identified.
-
For premenopausal ER+ breast cancer patients receiving CMF chemotherapy in an adjuvant setting, the presence of anemia during treatment was found to be a significant risk factor for the development of local recurrence.
-
FDA drug approval to change? Urinary incontinence in women; how metabolism of certain drugs can be predicted by genetic analysis; bowel preps may compromise renal function especially in the elderly according to a new study; FDA Actions.
-
The Women's Health Initiative (WHI) is a randomized controlled trial which is evaluating cancer and disease risk among healthy menopausal women aged 50-79 years.
-
-
By Alison Edelman, MD, MPH, Assistant Professor, Assistant Director of the Family Planning Fellowship Department of Obstetrics & Gynecology, Oregon Health & Science University, Portland, is Associate Editor for OB/GYN Clinical Alert.
